These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 12442513)

  • 1. [Microcirculation in gastric mucosa as related to its secretory activity in patients with peptic ulcer].
    Shcherbynina MB
    Lik Sprava; 2002; (5-6):24-6. PubMed ID: 12442513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effect of various antisecretory drugs on morphological changes in rat gastric mucosa in experimental stomach ulcers].
    Shcherbynina MB
    Fiziol Zh (1994); 2002; 48(3):72-5. PubMed ID: 12125288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eradication therapy of Helicobacter pylori directly induces apoptosis in inflammation-related immunocytes in the gastric mucosa--possible mechanism for cure of peptic ulcer disease and MALT lymphoma with a low-grade malignancy.
    Ohara T; Kanoh Y; Higuchi K; Arakawa T; Morisita T
    Hepatogastroenterology; 2003; 50(51):607-9. PubMed ID: 12828043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of lansoprazole on gastric ulcer healing and mucin content.
    Komuro Y; Ishii K; Miyake Y; Tanabe S; Oida M; Saigenji K
    J Clin Gastroenterol; 1995; 20 Suppl 2():S47-51. PubMed ID: 7594339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders.
    Barradell LB; Faulds D; McTavish D
    Drugs; 1992 Aug; 44(2):225-50. PubMed ID: 1382017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical evaluation of lansoprazole in the treatment of peptic ulcers: initial healing and prevention of relapse. Tohoku Peptic Ulcer Study Group.
    Asaki S; Sato A; Sakurada H; Takeda T; Hongo M; Toyota T
    J Clin Gastroenterol; 1995; 20 Suppl 2():S56-8. PubMed ID: 7594342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors affecting quality of ulcer healing after lansoprazole treatment.
    Ito G; Nakagawara M; Watanabe F; Ooi S; Nawano M; Hanai H; Kaneko E
    J Clin Gastroenterol; 1995; 20 Suppl 2():S62-6. PubMed ID: 7594344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Concerning the discussion article by I. A. Morozov "Choice of the gastroenterologist"].
    Gorshkov VA
    Klin Med (Mosk); 2002; 80(9):66-70. PubMed ID: 12416232
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical study on the pathophysiology and treatment of PPI-resistant ulcers.
    Ashida K; Sakaguchi M; Tanaka M; Takiuchi H; Egashira Y; Katsu K
    J Clin Gastroenterol; 1995; 20 Suppl 2():S67-71. PubMed ID: 7594345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Drug of the month. Lansoprazole (DakaR)].
    Scheen AJ
    Rev Med Liege; 1995 Mar; 50(3):133-4. PubMed ID: 7724943
    [No Abstract]   [Full Text] [Related]  

  • 11. Lansoprazole: a comprehensive review.
    Zimmermann AE; Katona BG
    Pharmacotherapy; 1997; 17(2):308-26. PubMed ID: 9085323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Lansoprazol ++ : a new proton pump inhibitor].
    Baczek J; Laskowiec G
    Pol Merkur Lekarski; 1998 Jun; 4(24):339-41. PubMed ID: 9771021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of acid peptic disease: focus on proton pump inhibitors. Proceedings of the 1st International Symposium on Lansoprazole. Athens, Greece, 24 September 1992.
    Aliment Pharmacol Ther; 1993; 7 Suppl 1():1-75. PubMed ID: 8098225
    [No Abstract]   [Full Text] [Related]  

  • 14. Lansoprazole: an update of its place in the management of acid-related disorders.
    Matheson AJ; Jarvis B
    Drugs; 2001; 61(12):1801-33. PubMed ID: 11693467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Antisecretory effect of losec and pariet in peptic ulcer therapy].
    Nemytin IuV; Makarov IuS; Pavlov AI; Kashchenko OI; Lezhenina NP; Golochalova TV
    Voen Med Zh; 2002 Oct; 323(10):44-6. PubMed ID: 12479006
    [No Abstract]   [Full Text] [Related]  

  • 16. [Proton pump inhibitors in the treatment of peptic ulcers resistant to H2-receptor antagonists].
    Asaka M; Kato M; Sato Y; Miyazaki T
    Nihon Rinsho; 1992 Jan; 50(1):104-10. PubMed ID: 1347322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peptic ulcer disease.
    Hawker P
    Practitioner; 1989 May; 233(1469):769-70, 773. PubMed ID: 2602318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gastroprotective effect of aparisthman, a diterpene isolated from Aparisthmium cordatum, on experimental gastric ulcer models in rats and mice.
    Hiruma-Lima CA; Gracioso JS; Toma W; Almeida AB; Paula AC; Brasil DS; Muller AH; Souza Brito AR
    Phytomedicine; 2001 Mar; 8(2):94-100. PubMed ID: 11315762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lansoprazole elevates the ratio of serum pepsinogen I v.s. pepsinogen II.
    Matsukawa Y; Nishinarita S; Kaneko M; Takei M; Murakami M; Horie T; Kawamura F; Arakawa Y; Kuwayama H; Kurosaka H
    Int J Clin Pharmacol Res; 1997; 17(4):127-32. PubMed ID: 9526173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Zollinger-Ellison syndrome. Advances in treatment of gastric hypersecretion and the gastrinoma.
    Jensen RT; Fraker DL
    JAMA; 1994 May; 271(18):1429-35. PubMed ID: 7513768
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.